Hold the applause: Big Pharma has little to brag about regarding 2016 R&D productivity
Exondys 51 stands out for more reasons than its unique and controversial status as the only Duchenne muscular dystrophy drug to make it through the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
